Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.
In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
